Locoregional Stomach Cancer

Gastric Adenocarcinoma

Female, 39 years

Patient Internal ID: 03598079

ICD-10 code

C16.2 Malignant Neoplasm of Body of Stomach

Diagnosis (Incl. Metastases/Stage) and Year

December 2019
Gastric Adenocarcinoma of Proximal Part ypT4aN2M0 LVI R0 G3 HER2(-). Disease progression in January 2021, Metastasis in the Ovaries.

Previous Treatment

Chemotherapy (FLOT scheme), Surgery (Gastrectomy), HIPEC (Cisplatin), Chemotherapy (FOLFOX scheme).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis for patients who received Gastric Resection and Postoperative Adjuvant Therapy.

Treatment Provided

Autologous DCV (7 doses) over a period of 6 months.

Patient Survival/Condition and Year
Date of Review: 02/12/2023

The patient has survived for 20 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy, Surgery and HIPEC, has extended patient survival by an estimate of around 6 months.